Ignyta, Inc. - Product Pipeline Review - 2016

  • ID: 3774220
  • Company Profile
  • 38 pages
  • Global Markets Direct
  • Ignyta
1 of 4
Ignyta, Inc. - Product Pipeline Review - 2016

Summary

‘Ignyta, Inc. - Product Pipeline Review - 2016’, provides an overview of the Ignyta, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Ignyta, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Ignyta, Inc.
- The report provides overview of Ignyta, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Ignyta, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Ignyta, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Ignyta, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Ignyta, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ignyta, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Ignyta, Inc. Snapshot

Ignyta, Inc. Overview

Key Information

Key Facts

Ignyta, Inc. - Research and Development Overview

Key Therapeutic Areas

Ignyta, Inc. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Ignyta, Inc. - Pipeline Products Glance

Ignyta, Inc. - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

Ignyta, Inc. - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Ignyta, Inc. - Drug Profiles

entrectinib

Product Description

Mechanism of Action

R&D Progress

RXDX-105

Product Description

Mechanism of Action

R&D Progress

taladegib

Product Description

Mechanism of Action

R&D Progress

RXDX-106

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit Protein kinase C-iota for Cancer

Product Description

Mechanism of Action

R&D Progress

Ignyta, Inc. - Pipeline Analysis

Ignyta, Inc. - Pipeline Products by Target

Ignyta, Inc. - Pipeline Products by Route of Administration

Ignyta, Inc. - Pipeline Products by Molecule Type

Ignyta, Inc. - Pipeline Products by Mechanism of Action

Ignyta, Inc. - Recent Pipeline Updates

Ignyta, Inc. - Dormant Projects

Ignyta, Inc. - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

RXDX-103

RXDX-104

RXDX-107

RXDX-108

Small Molecule 1 for Oncology

Small Molecule 2 for Oncology

Small Molecule 3 for Oncology

taladegib

Ignyta, Inc. - Locations And Subsidiaries

Head Office

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Ignyta, Inc., Key Information

Ignyta, Inc., Key Facts

Ignyta, Inc. - Pipeline by Indication, 2016

Ignyta, Inc. - Pipeline by Stage of Development, 2016

Ignyta, Inc. - Monotherapy Products in Pipeline, 2016

Ignyta, Inc. - Phase II, 2016

Ignyta, Inc. - Phase I, 2016

Ignyta, Inc. - Preclinical, 2016

Ignyta, Inc. - Pipeline by Target, 2016

Ignyta, Inc. - Pipeline by Route of Administration, 2016

Ignyta, Inc. - Pipeline by Molecule Type, 2016

Ignyta, Inc. - Pipeline Products by Mechanism of Action, 2016

Ignyta, Inc. - Recent Pipeline Updates, 2016

Ignyta, Inc. - Dormant Developmental Projects,2016

Ignyta, Inc. - Discontinued Pipeline Products, 2016

List of Figures

Ignyta, Inc. - Pipeline by Top 10 Indication, 2016

Ignyta, Inc. - Pipeline by Stage of Development, 2016

Ignyta, Inc. - Monotherapy Products in Pipeline, 2016

Ignyta, Inc. - Pipeline by Top 10 Target, 2016

Ignyta, Inc. - Pipeline by Route of Administration, 2016

Ignyta, Inc. - Pipeline by Molecule Type, 2016

Ignyta, Inc. - Pipeline Products by Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll